Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study).

被引：0
|
作者：
Meng, Xue
Zheng, Anping
Wang, Jun
Wang, Jianhua
Li, Guang
Zhu, Jun
Ma, Hu
Zhu, Xiaodong
Shi, Anhui
Dai, Chunhua
Yan, Senxiang
Wang, Buhai
Qu, Zhongyu
Han, Chun
Sun, Xindong
Ye, Ming
Fan, Ruitai
Huerxidan, Ni Yazi
Wang, Xiaohong
Yu, Jinming
机构：
[1] Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[2] Anyang Canc Hosp, Anyang, Peoples R China
[3] Hebei Med Univ, Hosp 4, Dept Radiat Oncol, Shijiazhuang, Peoples R China
[4] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Peoples R China
[5] China Med Univ, Hosp 1, Dept Radiat Oncol, Shenyang, Peoples R China
[6] Jiangsu Canc Hosp, Nanjing, Peoples R China
[7] Zunyi Med Univ, Affiliated Hosp 2, Zunyi, Guizhou, Peoples R China
[8] Guangxi Med Univ, Affiliated Tumor Hosp, Nanning, Guangxi, Peoples R China
[9] Beijing Canc Hosp, Beijing, Peoples R China
[10] Jiangsu Univ, Affiliated Hosp, Zhenjiang, Jiangsu, Peoples R China
[11] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[12] Northern Jiangsu Peoples Hosp, Yangzhou, Peoples R China
[13] Henan Prov Nanyang Cent Hosp, Nanyang, Peoples R China
[14] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[15] Shandong First Med Univ, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[16] Shandong Acad Med Sci, Jinan, Peoples R China
[17] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai, Peoples R China
[18] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[19] Xinjiang Med Univ, Affiliated Hosp 1, Urumqi, Peoples R China
[20] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[21] Shandong Canc Hosp & Inst, Jinan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4016
引用
收藏
页数：1
相关论文
共 31 条
  • [21] Preliminary results from the multicenter, randomized phase III trial (SCIENCE): Comparing chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant treatment in resectable locally advanced esophageal squamous cell carcinoma.
    Leng, Xuefeng
    He, Wenwu
    Lyu, Jiahua
    Gong, Lei
    Hu, Tongchen
    Zhou, Haining
    Peng, Lin
    Liu, Guangyuan
    Wang, Kangning
    Fang, Qiang
    Qi, Yunxiang
    Zhou, Yehan
    Zhang, Wencheng
    Tang, Peng
    Li, Tao
    Han, Yongtao
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : LBA329 - LBA329
  • [22] ORIENT-15: A randomized, multicenter, double-blind, Phase III study of sintilimab plus paclitaxel and cisplatin (TP) versus placebo plus TP as first-line treatment in patients with unresectable locally advanced or metastatic esophageal squamous cell carcinoma
    Shen, Lin
    Lu, Zhihao
    Xu, Linxinyu
    Wang, Yan
    Zhou, Hui
    Liu, Ying
    CANCER RESEARCH, 2019, 79 (13)
  • [23] NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)
    Guirado, M.
    Majem, M.
    Massuti Sureda, B.
    de las Penas Bataller, R.
    Ortega Granados, A. L.
    Isla Casado, M. D.
    Domine Gomez, M.
    Marse Fabregat, R.
    Sala, M. A.
    Paredes Lario, A.
    Moran Bueno, M. T.
    Vazquez Estevez, S.
    Coves Sarto, J.
    Gonzalez-Larriba, J. L.
    Sanchez Torres, J. M.
    Vicente, D.
    Farre Bernado, N.
    Fernandez-Fornos, L.
    Varcarcel, F.
    Provencio, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 594 - 594
  • [24] Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002)
    Shang, Xiaobin
    Zhang, Wencheng
    Zhao, Gang
    Liang, Fei
    Zhang, Chen
    Yue, Jie
    Duan, Xiaofeng
    Ma, Zhao
    Chen, Chuangui
    Pang, Qingsong
    Zhang, Weihong
    Liu, Liang
    Ren, Xiubao
    Meng, Bin
    Zhang, Peng
    Ma, Yegang
    Zhang, Lin
    Li, Hecheng
    Kang, Xiaozheng
    Li, Yin
    Jiang, Hongjing
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Concurrent chemotherapy and external radiation therapy: An open label non-inferiority phase III randomized controlled trial of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma: CONCERT trial
    Sharma, A.
    Chaudhary, M. K.
    Thakar, A.
    Bhaskar, S.
    Sikka, K.
    Pramanik, R.
    Biswas, A.
    Singh, C. A.
    Sahoo, R. K.
    Deo, S.
    Kumar, R.
    Thulkar, S.
    Kakkar, A.
    Seth, S.
    Sreenivas, V.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] NORA trial (GECP 15/02): First efficacy results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC).
    Isla, Dolores
    Majem, Margarita
    Guirado, Maria
    Massuti, Bartomeu
    De Las Penas, Ramon
    Granados, Ana Laura Ortega
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
    Tanzawa, Shigeru
    Makiguchi, Tomonori
    Tasaka, Sadatomo
    Inaba, Megumi
    Ochiai, Ryosuke
    Nakamura, Junya
    Inoue, Koji
    Kishikawa, Takayuki
    Nakashima, Masanao
    Fujiwara, Keiichi
    Kohyama, Tadashi
    Ishida, Hiroo
    Kuyama, Shoichi
    Miyazawa, Naoki
    Nakamura, Tomomi
    Miyawaki, Hiroshi
    Oda, Naohiro
    Ishikawa, Nobuhisa
    Morinaga, Ryotaro
    Kusaka, Kei
    Miyamoto, Yosuke
    Yokoyama, Toshihide
    Matsumoto, Chiaki
    Tsuda, Takeshi
    Ushijima, Sunao
    Shibata, Kazuhiko
    Shibayama, Takuo
    Bessho, Akihiro
    Kaira, Kyoichi
    Misumi, Toshihiro
    Shiraishi, Kenshiro
    Matsutani, Noriyuki
    Seki, Nobuhiko
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [28] Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase III Clinical Trial
    Zhang, J.
    Li, M.
    Zhang, K.
    Zheng, A.
    Li, G.
    Chen, S.
    Chen, X.
    Li, X.
    Sheng, Y.
    Sun, X.
    Liu, L.
    Liu, X.
    Li, J.
    Wang, J.
    Ge, H.
    Ye, S.
    Pang, Q.
    Zhang, X.
    Dai, S.
    Li, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S15 - S15
  • [29] Induction docetaxel platinum 5-FU (TPF) followed by cetuximab-radiotherapy (cetux-RT) versus concurrent chemo-radiotherapy (CT/RT) in patients with N2b/c-N3 non operated stage III-IV squamous cell cancer of the head and neck (SCCHN): Results of the GORTEC 2007-02 phase III randomized trial.
    Geoffrois, Lionnel
    Martin, Laurent
    Garaud, Pascal
    De Raucourt, Dominique
    Miny, Joelle
    Maingon, Philippe
    Lafond, Cedrik
    Tuchais, Claude
    Sire, Christian
    Babin, Emmanuel
    Coutte, Alexandre
    Tao, Yungan
    Rolland, Frederic
    Girard-Calais, Marie Helene
    Bourhis, Jean
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] INTERIM ANALYSIS OF THE SPANISH LUNG CANCER GROUP (SLCG) RANDOMIZED PHASE II TRIAL OF THORACIC RADIOTHERAPY (RT) CONCURRENT WITH CISPLATIN (P) PLUS ORAL VINORELBINE (OV) OR ETOPOSIDE (E) FOR UNRESECTABLE LOCALLY ADVANCED (LA) STAGE III NON-SMALL CELL LUNG CANCER (NSCLC). (GECP10/02)
    Isla, Dolores
    De Las Penas, Ramon
    Martinez-Banaclocha, Natividad
    Massuti, Bartomeu
    Angeles Sala, Maria
    Bover, Isabel
    Marse, Raquel
    Insa, Amelia
    Moran, Teresa
    Artal, Angel
    Diz, Pilar
    Gomez-Codina, Jose
    Laura Ortega, Ana
    Gutierrez, Vanesa
    Munoz, Jose
    Alvarez De Mon, Melchor
    Camps, Carlos
    Garcia-Gomez, Ramon
    Jurado, Jose M.
    Ponce-Aix, Santiago
    Provencio, Mariano
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S408 - S408
1234